Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Short Review

Current Attitudes to the Therapy of Vasculitis

Jayne D.

Author affiliations

Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, Cambridge, UK

Related Articles for ""

Kidney Blood Press Res 2003;26:231–239

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

Published online: September 24, 2003
Issue release date: 2003

Number of Print Pages: 9
Number of Figures: 5
Number of Tables: 1

ISSN: 1420-4096 (Print)
eISSN: 1423-0143 (Online)

For additional information: https://www.karger.com/KBR


First-Page Preview
Abstract of Short Review

References

  1. Panel R: Treatment of polyarteritis nodosa with cortisone: Results after three years. Br Med J 1960;1399:1400.
  2. Walton E: Giant cell granuloma of the respiratory tract (Wegener’s granulomatosis). Br Med J 1958;ii:265–270.
  3. Fauci AS, Haynes BF, Katz P, Wolff SM: Wegener’s granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76–85.
  4. Guillevin L, Lhote F, Jarrousse B, Fain O: Treatment of polyarteritis nodosa and Churg-Strauss syndrome: A meta- analysis of 3 prospective controlled trials including 182 patients over 12 years. Ann Med Interne (Paris) 1992;143:405–416.
  5. Jayne D: Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 2001;13:48–55.
  6. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS: Etanercept combined with conventional treatment in Wegener’s granulomatosis: A six-month open-label trial to evaluate safety. Arthritis Rheum 2001;44:1149–1154.
  7. Lockwood CM, Thiru S, Isaacs JD, Hale G, Waldmann H: Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993;341:1620–1622.
  8. Stegeman CA, Cohen Tervaert JW, De Jong PE, Kallenberg CG: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996;335:16–20.
  9. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187–192.
  10. van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, et al: Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1985;i:425–429.
  11. Hagen EC, Andrassy K, Csernok E, Daha MR, Gaskin G, Gross WL, et al: Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA): A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods 1996;196:1–15.
  12. Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, et al: Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int 2002;61:80–89.
  13. Jayne D, Rasmussen N, Andrassy K, Bacon P, Cohen Tervaert JW, Dadoniene J, et al: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36–44.
  14. de Groot K, Gross WL, Herlyn K, Reinhold-Keller E: Development and validation of a disease extent index for Wegener’s granulomatosis. Clin Nephrol 2001;55:31–38.
  15. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al: Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994;87:671–678.
  16. Bacon PA, Moots RJ, Exley A, Luqmani R, Rasmussen N: VITAL (Vasculitis Integrated Assessment Log) assessment of vasculitis. Clin Exp Rheumatol 1995;13:275–278.
  17. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al: A disease-specific activity index for Wegener’s granulomatosis: Modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001;44:912–920.
  18. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Carruthers DM, Moots R: Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol 1998;37:57–63.
  19. Ware JE, Jr., Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–483.
  20. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al: Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med 1992;116:488–498.
  21. Rasmussen N: European therapeutic trials in ANCA-associated systemic vasculitis: Disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immunol 1995;101(suppl 1):29–34.
  22. Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG, et al: Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study. Arthritis Rheum 2000;43:2025–2033.
  23. Jayne DR, Gaskin G, Pusey CD, Lockwood CM: ANCA and predicting relapse in systemic vasculitis. Q J Med 1995;88:127–133.
  24. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, De Jong PE, Kallenberg CG: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994;120:12–17.
  25. Esnault VL, Audrain MA, Sesboue R: Alpha-1-antitrypsin phenotyping in ANCA-associated diseases: One of several arguments for protease/antiprotease imbalance in systemic vasculitis. Exp Clin Immunogenet 1997;14:206–213.
  26. Huang D, Giscombe R, Zhou Y, Lefvert AK: Polymorphisms in CTLA-4 but not tumor necrosis factor-alpha or interleukin 1beta genes are associated with Wegener’s granulomatosis. J Rheumatol 2000;27:397–401.
  27. Leib ES, Restivo C, Paulus HE: Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 1979;67:941–947.
  28. Fauci AS, Katz P, Haynes BF, Wolff SM: Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979;301:235–238.
  29. Guillevin L, Jarrousse B, Lok C, Lhote F, Jais JP, Thi Huong Du D, et al: Long-term follow-up after treatment of polyarteritis nodosa and Churg- Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 1991;18:567–574.
  30. de Groot K, Muhler M, Reinhold-Keller E, Paulsen J, Gross WL: Induction of remission in Wegener’s granulomatosis with low dose methotrexate. J Rheumatol 1998;25:492–495.
  31. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS: An analysis of forty-two Wegener’s granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995;38:608–613.
  32. Langford CA, Talar-Williams C, Sneller MC: Use of methotrexate and glucocorticoids in the treatment of Wegener’s granulomatosis: Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000;43:1836–1840.
  33. Stone JH, Tun W, Hellman DB: Treatment of non-life threatening Wegener’s granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 1999;26:1134–1139.
  34. Lockwood CM, Pinching AJ, Sweny P, Rees AJ, Pussell B, Uff J, et al: Plasma-exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis. Lancet 1977;i:63–67.
  35. de Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Nolle B, et al: Therapy for the maintenance of remission in sixty-five patients with generalized Wegener’s granulomatosis: Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996;39:2052–2061.
  36. Reinhold-Keller E, Fink CO, Herlyn K, Gross WL, de Groot K: High rate of renal relapse in 71 patients with Wegener’s granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002;47:326–332.
  37. Reinhold-Keller E, Kekow J, Schnabel A, Schmitt WH, Heller M, Beigel A, et al: Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener’s granulomatosis. Arthritis Rheum 1994;37:919–924.
  38. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS: Treatment of Wegener’s granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990;89:403–410.
  39. de Groot K, Adu D, Savage C: The value of pulse cyclophosphamide in ANCA-associated vasculitis: Meta-analysis and critical review. Nephrol Dial Transplant 2001;16:2018–2027.
  40. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al: A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 1997;40:2187–2198.
  41. Adu D, Pall A, Luqmani RA, Richards NT, Howie AJ, Emery P, et al: Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Q J Med 1997;90:401–409.
  42. Haubitz M, Schellong S, Gobel U, Schurek HJ, Schaumann D, Koch KM, et al: Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study. Arthritis Rheum 1998;41:1835–1844.
  43. Guillevin L, Cohen P, Mahr A, Arene JP, Mouthon L, Puechal X, et al: Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003;49:93–100.
  44. Jayne DR, Rasmussen N: Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997;72:737–747.
  45. Tyndall A: Immunoablation and haemopoietic stem cell transplantation for severe autoimmune disease with special reference to systemic lupus erythematosus. Lupus 2001;10:214–215.
  46. Hensel M, Fiehn C, Ho AD: Stem cell transplantation in primary systemic vasculitis. Med Klin 2003;98:13–18.
  47. Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M, et al: A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum 2002;46:2301–2309.
  48. Guillevin L, Cevallos R, Durand-Gasselin B, Lhote F, Jarrousse B, Callard P: Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome: Indications of plasma exchanges, meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Ann Med Interne (Paris) 1997;148:198–204.
  49. Gianviti A, Trompeter RS, Barratt TM, Lythgoe MF, Dillon MJ: Retrospective study of plasma exchange in patients with idiopathic rapidly progressive glomerulonephritis and vasculitis. Arch Dis Child 1996;75:186–190.
  50. Szpirt WM RN: Plasma exchange and cyclosporin A in Wegener’s granulomatosis: A controlled study. Int J Artif Organs 1996;10:501.
  51. Guillevin L, Lhote F, Cohen P, Jarrousse B, Lortholary O, Genereau T, et al: Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis: A prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995;38:1638–1645.
  52. Cole E, Cattran D, Magil A, Greenwood C, Churchill D, Sutton D, et al: A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis 1992;20:261–269.
  53. Guillevin L, Fain O, Lhote F, Jarrousse B, Thi Huong D, Bussel A, et al: Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome: A prospective, randomized trial in 78 patients. Arthritis Rheum 1992;35:208–215.
  54. Gaskin G, Pusey C: Long-term outcome after immunosuppression and plasma exchange for severe vasculitis-associated glomerulonephritis. J Am Soc Nephrol 1999;10:101A.
  55. Gallagher H, Kwan J, Jayne D: Pulmonary renal syndrome: A 4-year single centre experience. Am J Kidney Dis 2002;39:42–47.
  56. Jayne DR, Chapel H, Adu D, Misbah S, O’Donoghue D, Scott D, et al: Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 2000;93:433–439.
  57. Altmeyer P, Seifarth D, Bacharach-Buhles M: High dosage intravenous immunoglobulin (IVIG) therapy in therapy-refractory ANCA-negative, necrotizing vasculitis. Hautarzt 1999;50:853–858.
  58. Levy Y, Sherer Y, George J, Langevitz P, Ahmed A, Bar-Dayan Y, et al: Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 1999;119:231–238.
  59. Jayne DR, Lockwood CM: Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996;35:1150–1153.
  60. Richter C, Schnabel A, Csernok E, de Groot K, Reinhold-Keller E, Gross WL: Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995;101:2–7.
  61. Kazatchkine M, Mouthon L, Kaveri SV: Immunomodulatory effects of intravenous immunoglobulins. Ann Méd Interne (Paris) 2000;151(suppl 1):1S13–1S18.
  62. Boman S, Ballen JL, Seggev JS: Dramatic responses to intravenous immunoglobulin in vasculitis. J Intern Med 1995;238:375–377.
  63. Bahadoran P, De Bandt M, Echard M, Jarrousse B, Guillevin L: Failure of intravenous immunoglobulins in certain systemic diseases: 5 cases. Presse Méd 1993;22:1175–1178.
  64. Cohen Tervaert JW, Popa ER, Bos NA: The role of superantigens in vasculitis. Curr Opin Rheumatol 1999;11:24–33.
  65. Cohen Tervaert JW, Huitema MG, Hene RJ, Sluiter WJ, The TH, van der Hem GK, et al: Prevention of relapses in Wegener’s granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990;336:709–711.
  66. Westman KW, Selga D, Bygren P, Segelmark M, Baslund B, Wiik A, et al: Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody. Kidney Int 1998;53:1230–1236.
  67. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, et al: Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124:477–484.
  68. Hoffman GS, Leavitt RY, Fauci AS: Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989;32:1626–1627.
  69. Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P, et al: Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: Analysis of four prospective trials including 278 patients. Arthritis Rheum 2001;44:666–675.
  70. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al: Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study. Am J Kidney Dis 2003;41:776–784.
  71. Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, et al: Determinants of outcome in ANCA-associated glomerulonephritis: A prospective clinico-histopathological analysis of 96 patients. Kidney Int 2002;62:1732–1742.
  72. Vergunst CE, van Gurp E, Hagen EC, van Houwelingen HC, Hauer HA, Noel LH, et al: An index for renal outcome in ANCA-associated glomerulonephritis. Am J Kidney Dis 2003;41:532–538.
    External Resources
  73. Gisslen K, Wieslander J, Westberg G, Herlitz H: Relationship between anti-neutrophil cytoplasmic antibody determined with conventional binding and the capture assay, and long-term clinical course in vasculitis. J Intern Med 2002;251:129–135.
  74. Haubitz M, de Groot K: Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis. Clin Nephrol 2002;57:421–424.
  75. Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ: Mycophenolate mofetil for maintenance therapy of Wegener’s granulomatosis and microscopic polyangiitis: A pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999;10:1965–1971.
  76. Metzler ILF: Maintenance of remission with leflunomide in Wegener’s granulomatois. Arthritis Rheum 1999;42.
  77. Haubitz M, Koch KM, Brunkhorst R: Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant 1998;13:2074–2076.
  78. Birck R, Warnatz K, Lorenz HM, Choi M, Haubitz M, Grunke M, et al: 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: A six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003;14:440–447.
  79. Hagen EC, de Keizer RJ, Andrassy K, van Boven WP, Bruijn JA, van Es LA, et al: Compassionate treatment of Wegener’s granulomatosis with rabbit anti-thymocyte globulin. Clin Nephrol 1995;43:351–359.
  80. Lockwood CM: Refractory Wegener’s granulomatosis: A model for shorter immunotherapy of autoimmune diseases. J R Coll Physns Lond 1998;32:473–478.
  81. Kneitz C, Wilhelm M, Tony HP: Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 2002;206:519–527.
  82. Specks U, Fervenza FC, McDonald TJ, Hogan MC: Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44:2836–2840.
  83. Booth AD, Jefferson HJ, Ayliffe W, Andrews PA, Jayne DR: Safety and efficacy of TNF-alpha blockade in relapsing vasculitis. Ann Rheum Dis 2002;61:559.
  84. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, et al: Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: An open pilot study on 10 patients. Rheumatology (Oxford) 2002;41:1126–1132.
  85. Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD: Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev 2002;1:338–347.
  86. Hoffman GS, Drucker Y, Cotch MF, Locker GA, Easley K, Kwoh K: Wegener’s granulomatosis: Patient-reported effects of disease on health, function, and income. Arthritis Rheum 1998;41:2257–2262.

Article / Publication Details

Published online: September 24, 2003
Issue release date: 2003

Number of Print Pages: 9
Number of Figures: 5
Number of Tables: 1

ISSN: 1420-4096 (Print)
eISSN: 1423-0143 (Online)

For additional information: https://www.karger.com/KBR


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.